Valuation : Compass Therapeutics, Inc.

Market Cap 429M 369M 347M 317M 593M 40.47B 595M 4.1B 1.59B 20.76B 1.61B 1.57B 66.89B P/E 2026 *
-4.75x
P/E 2027 * -4.3x
Enterprise Value 279M 240M 226M 206M 385M 26.31B 387M 2.67B 1.03B 13.5B 1.05B 1.02B 43.48B EV / Sales 2026 *
-
EV / Sales 2027 * 13.2x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week-0.83%
Current month-0.42%
1 month+20.20%
3 months+11.74%
6 months-58.17%
Current year-55.68%
1 week 2.29
Extreme 2.29
2.46
1 month 1.87
Extreme 1.87
2.55
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/29/26 Buy

Controller/Auditor

15,000 0.0083%
4/29/26 Buy

General Counsel

25,000 0.0139%
4/29/26 Free

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%-0.83%-29.38%0.00% 429M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.20%+0.15%+38.36%+167.15% 27.95B
Weighted average by Cap. -1.52%+0.17%+42.18%+144.86%

Financials

2026 *2027 *
Net sales - 22.39M 19.27M 18.13M 16.56M 30.98M 2.11B 31.07M 214M 83.13M 1.08B 84.09M 82.26M 3.49B
Net income -94.04M -80.92M -76.14M -69.55M -130M -8.88B -130M -900M -349M -4.56B -353M -345M -14.68B -110M -94.51M -88.92M -81.23M -152M -10.37B -152M -1.05B -408M -5.32B -412M -403M -17.14B
Net Debt -150M -129M -121M -111M -208M -14.16B -208M -1.44B -557M -7.27B -563M -551M -23.41B -133M -114M -108M -98.36M -184M -12.56B -185M -1.27B -494M -6.44B -499M -489M -20.76B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
26-09-04 $2.380 +0.42% 2,548,324
26-09-03 $2.370 -2.47% 2,559,952
26-09-02 $2.430 +5.19% 2,539,819
26-09-01 $2.310 -3.35% 1,512,903
26-08-31 $2.390 -0.42% 3,523,042
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.380USD
Average target price
8.917USD
Spread / Average Target
+274.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock